BACKGROUND: Brain natriuretic peptides (BNPs) are useful in the assessment of heart failure, left ventricular dysfunction, and acute coronary syndromes. METHODS: We performed a multicenter evaluation of the automated Roche NT-proBNP assay and compared its performance to the Biosite Triage BNP assay. RESULTS: The N-terminal (1-76) pro brain natriuretic peptide (NT-proBNP) method is precise (CV<or=6.1%), has a wide dynamic measuring range (30-35000 ng/l), is free from common interferences, and does not cross-react with BNP. EDTA or heparinized plasma samples collected in glass or plastic tubes can be used, and samples are stable at room temperature or 4 degrees C for up to 3 days. In contrast, the Biosite BNP assay has >2-fold higher CV, and plasma samples are more labile when stored at room temperature and 4 degrees C. Comparison studies showed a reasonable correlation between NT-proBNP and BNP assays, with a substantially higher slope bias of 6-20 for the NT-proBNP assay. CONCLUSIONS: The automated Roche NT-proBNP assay has good analytical performance and better precision than the Biosite BNP assay. Unlike BNP, NT-proBNP is stable in EDTA plasma for 3 days at room temperature or longer at 4 degrees C. The Roche NT-proBNP is fully automated and will accommodate the testing of large numbers of clinical samples for assessing cardiac dysfunction.
BACKGROUND: Brain natriuretic peptides (BNPs) are useful in the assessment of heart failure, left ventricular dysfunction, and acute coronary syndromes. METHODS: We performed a multicenter evaluation of the automated Roche NT-proBNP assay and compared its performance to the Biosite Triage BNP assay. RESULTS: The N-terminal (1-76) pro brain natriuretic peptide (NT-proBNP) method is precise (CV<or=6.1%), has a wide dynamic measuring range (30-35000 ng/l), is free from common interferences, and does not cross-react with BNP. EDTA or heparinized plasma samples collected in glass or plastic tubes can be used, and samples are stable at room temperature or 4 degrees C for up to 3 days. In contrast, the Biosite BNP assay has >2-fold higher CV, and plasma samples are more labile when stored at room temperature and 4 degrees C. Comparison studies showed a reasonable correlation between NT-proBNP and BNP assays, with a substantially higher slope bias of 6-20 for the NT-proBNP assay. CONCLUSIONS: The automated Roche NT-proBNP assay has good analytical performance and better precision than the Biosite BNP assay. Unlike BNP, NT-proBNP is stable in EDTA plasma for 3 days at room temperature or longer at 4 degrees C. The Roche NT-proBNP is fully automated and will accommodate the testing of large numbers of clinical samples for assessing cardiac dysfunction.
Authors: Harm H H Feringa; Don Poldermans; Patrick Klein; Jerry Braun; Robert J M Klautz; Ron T van Domburg; Arnoud van der Laarse; Ernst E van der Wall; Robert A E Dion; Jeroen J Bax Journal: Int J Cardiovasc Imaging Date: 2006-08-29 Impact factor: 2.357
Authors: Bonnie Ky; Benjamin French; Kosha Ruparel; Nancy K Sweitzer; James C Fang; Wayne C Levy; Douglas B Sawyer; Thomas P Cappola Journal: J Am Coll Cardiol Date: 2011-07-19 Impact factor: 24.094
Authors: Lisa C Costello-Boerrigter; Guido Boerrigter; Margaret M Redfield; Richard J Rodeheffer; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Denise M Heublein; John C Burnett Journal: J Am Coll Cardiol Date: 2006-01-04 Impact factor: 24.094
Authors: Ebbing P de Jong; Susan K van Riper; Joseph S Koopmeiners; John V Carlis; Timothy J Griffin Journal: Clin Chim Acta Date: 2011-08-24 Impact factor: 3.786
Authors: Lori B Daniels; Gail A Laughlin; Paul Clopton; Alan S Maisel; Elizabeth Barrett-Connor Journal: J Am Coll Cardiol Date: 2008-08-05 Impact factor: 24.094